Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
SGHT vs ECOR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SGHT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–0 Matrix Metrics)
SGHT Overall Winner
6-Pillar Tally: SGHT 3 – 2 ECOR (1 Tie)
Matrix Metrics: SGHT 8 – 0 ECOR
As of Nov 20, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SGHT carries a Unified Composite Score of 53.2/100 (HOLD) at $10.18 (N/M Forward P/E, -20.2% operating margin), whereas ECOR carries 44.5/100 (HOLD) at $4.42 (N/M Forward P/E, -33.1% operating margin).
- Technical & Structure Timing Caution: SGHT trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.2); meanwhile ECOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SGHT vs ECOR
SGHT
Head-to-Head Winner
Sight Sciences, Inc. Common Stock
$10.18
-4.14% 1D
Market Cap
$590.2M
TTM Revenue
$88M
Forward P/E
N/M
Beta / 30D Vol
1.09β · 48% Vol
Unified Composite Score
53.2
HOLD
Tech 39.0
Fund 54.0
Flow 70.0
Mom 60.0
Weinstein Technical Phase
Markup · Hold / add on dips
ECOR
electroCore, Inc. Common Stock
$4.42
-8.87% 1D
Market Cap
$44.7M
TTM Revenue
$38M
Forward P/E
N/M
Beta / 30D Vol
1.55β · 155% Vol
Unified Composite Score
44.5
HOLD
Tech 30.0
Fund 60.0
Flow 50.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (SGHT 3 – 2 ECOR)
1. Valuation Multiples
ECOR
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
6.3x
1.3x
2. Growth & Scale
SGHT
Revenue Growth (YoY)
+25.2%
+11.5%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$88M
$38M
Market Cap
$590.2M
$44.7M
3. Profitability & Quality
SGHT
Gross Margin
87.7%
87.7%
Operating Margin
-20.2%
-33.1%
Net Profit Margin
-32.1%
-33.5%
Return on Equity (ROE)
-50.1%
-478.7%
4. Balance Sheet & Cash Flow
ECOR
Cash Generation (TTM)
-$17M
-$6.9M
Cash Flow Margin
-19.1%
-18.1%
Net Cash / Leverage
$35M Net Cash
$4.6M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SGHT
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
78.7% (8th %ile)
N/A (N/A)
Put/Call OI Skew
0.01x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SGHT (8) vs ECOR (0)| Institutional Metric | SGHT | ECOR | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $590.2M | $44.7M | SGHT | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +25.2% | +11.5% | SGHT | |
| Operating Margin (TTM) | -20.2% | -33.1% | SGHT | |
| Net Profit Margin | -32.1% | -33.5% | SGHT | |
| Return on Equity (ROE) | -50.1% | -478.7% | SGHT | |
| 52-Week Range Position | 83% ($3–$12) | 6% ($4–$13) | SGHT | |
| Beta / 30D Volatility | 1.09β · 48% Vol | 1.55β · 155% Vol | SGHT | |
| Unified Institutional Score | 53.2 / 100 (HOLD) | 44.5 / 100 (HOLD) | SGHT | |
| Trailing 12M Revenue (USD) | $88M | $38M | Scale | |
| Gross Profit Margin (TTM) | 87.7% | 87.7% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 6.3x EV/Rev | N/M PEG · 1.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$17M ($35M Net Cash) | -$6.9M ($4.6M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SGHT +52.34 pp
3M Horizon
SGHT +75.68 pp
6M Horizon
SGHT +136.12 pp
1Y Horizon
SGHT +56.33 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SGHT Revenue | ECOR Revenue | SGHT Op. Margin | ECOR Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -5494.1% | ECOR |
| FY2019 | N/A | $0M | N/A | -1928.2% | ECOR |
| FY2020 | $30M | $0M | -116.5% | -707.9% | SGHT |
| FY2021 | $50M | $10M | -105.2% | -367.7% | SGHT |
| FY2022 | $70M | $10M | -117.7% | -266.2% | SGHT |
| FY2023 | $80M | $20M | -70.7% | -120.2% | SGHT |
| FY2024 | $80M | $30M | -63.3% | -48.3% | ECOR |
| FY2025 | $80M | $30M | -48.0% | -41.1% | ECOR |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SGHT
CONSOLIDATION
Current IV
78.7%
IV Percentile
8th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact SGHT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ECOR
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SGHT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ECOR Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ SGHT vs ECOR Key Questions & Quantitative Answers
As of Nov 20, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SGHT carries a Unified Composite Score of 53.2/100 (HOLD) at $10.18 (N/M Forward P/E, -20.2% operating margin), whereas ECOR carries 44.5/100 (HOLD) at $4.42 (N/M Forward P/E, -33.1% operating margin). Technical & Structure Timing Caution: SGHT trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.2); meanwhile ECOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SGHT leads the Growth & Scale pillar: SGHT posts +25.2% YoY revenue growth and +0.0% YoY earnings growth on $88M TTM revenue (87.7% gross margin, -20.2% operating margin), compared with ECOR at +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SGHT cumulative revenue shifted +166.7% while ECOR shifted +200.0%. In operating R&D and SG&A reinvestment, SGHT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ECOR.
ECOR screens cheaper on headline valuation multiples. SGHT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.3x EV/Revenue (-19.1% FCF margin), whereas ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-18.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGHT (-50.1% ROE) versus ECOR (-478.7% ROE) capital efficiency.
In options market volatility and institutional positioning, SGHT carries 78.7% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.09β · 48% Vol realized risk). By comparison, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 155% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ECOR vs SGHT · Reverse Pair
SGHT vs CTKB
· Sector Peer
SGHT vs TMCI
· Sector Peer
SGHT vs RXST
· Sector Peer
ECOR vs PRPO
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma